Goldenwell Biotech, Inc. GWLL
0.65 USD 0.00 (+0.00%)
At closeNov 3, 2026, 4:00 PM EST
0.65 Day range 0.65
0.51 52-week range 6.00
- YTD
- -77.59%
- 1 year
- -90.71%
Financial health
Altman Z-Score
-20.67 Distress zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
1 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
C2 / 5 overall
- DCF 1
- Return on Equity 5
- Return on Assets 1
- Debt / Equity 1
- P/E 1
- P/B 1
Valuation
P/E -967×
FY 2019 5y median -154× FY 2025
P/S 5220000×
FY 2019 5y median 2415× FY 2025
P/B -835×
FY 2019 5y median 66.7× FY 2025
P/FCF -12687×
FY 2019 5y median -131× FY 2025
EV/EBITDA -2534×
FY 2019 5y median -161× FY 2025
EV/Sales 5221251×
FY 2019 5y median 2453× FY 2025
FCF Yield -0.0%
FY 2019 5y median -0.8% FY 2025
Profitability
Gross Margin 21.8%
FY 2019 5y median 47.4% FY 2025
Operating Margin -206047.3%
FY 2019 5y median -4995.5% FY 2025
Net Margin -539038.2%
FY 2019 5y median -4995.5% FY 2025
ROE 86.3%
FY 2019 5y median -38.8% FY 2025
ROIC 172.4%
FY 2019 5y median -51.7% FY 2025
ROA -820.8%
FY 2019 5y median -58.7% FY 2025
Growth (YoY)
Revenue -60.4%
FY 2019 FY 2025
Operating Income 7.9%
FY 2019 FY 2025
EPS (diluted) -130.8%
FY 2019 FY 2025
Free Cash Flow 81.6%
FY 2019 FY 2025
Financial Health
Current Ratio 2.0×
FY 2019 5y median 8.3× FY 2025
Quick Ratio 0.3×
FY 2019 5y median 1.7× FY 2025
Debt / Equity -0.3×
FY 2019 5y median 0.1× FY 2025
Net Debt / EBITDA -0.6×
FY 2019 5y median -0.4× FY 2025
Interest Coverage -13.5×
FY 2019 5y median 0.0× FY 2025
Dividends
Dividend Yield 0.0%
FY 2019 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2019 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31